Paul Romness, Chair, CEO and President of OS Therapies, discusses the company’s OST-HER2 immunotherapy and its potential to improve outcomes and reduce recurrence for children and young adults battling osteosarcoma.
February 7, 2023
Paul Romness, Chair, CEO and President of OS Therapies, discusses the company’s OST-HER2 immunotherapy and its potential to improve outcomes and reduce recurrence for children and young adults battling osteosarcoma.
Other Interviews
